Israel - English - Ministry of Health

lundbeck israel ltd - aripiprazole as monohydrate - powder and solvent for prolonged-release suspension for injection - aripiprazole as monohydrate 300 mg/vial - aripiprazole - abilify maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Israel - English - Ministry of Health

lundbeck israel ltd - aripiprazole as monohydrate - powder and solvent for prolonged-release suspension for injection - aripiprazole as monohydrate 400 mg/vial - aripiprazole - abilify maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Israel - English - Ministry of Health

lundbeck israel ltd - aripiprazole as monohydrate - powder and solvent for prolonged-release suspension for injection - aripiprazole as monohydrate 400 mg/vial - aripiprazole - abilify maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Israel - English - Ministry of Health

lundbeck israel ltd - aripiprazole as monohydrate - powder and solvent for prolonged-release suspension for injection - aripiprazole as monohydrate 400 mg/vial - aripiprazole - abilify maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

artesan pharma gmbh & co. kg - carvedilol - tablets - 6,25mg

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - brigatinib -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - brigatinib -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - brigatinib -

Canada - English - Health Canada

organon canada inc. - desogestrel; ethinyl estradiol - tablet - 0.15mg; 0.03mg - desogestrel 0.15mg; ethinyl estradiol 0.03mg - contraceptives